• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2012 NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: SoundBite™ hearing system
2012 NIHR Horizon Scanning Centre (NIHR HSC) Femtosecond lasers for cataract surgery
2012 NIHR Horizon Scanning Centre (NIHR HSC) Sensimed triggerfish® for 24-hour monitoring of changes in intraocular pressure in glaucoma
2012 NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Argus II™ retinal prosthesis system for peripheral retinal degeneration
2012 NIHR Horizon Scanning Centre (NIHR HSC) Lubiprostone (Amitiza) for chronic idiopathic constipation
2012 NIHR Horizon Scanning Centre (NIHR HSC) Lubiprostone (Amitiza) for opioid-induced constipation in patients with chronic non-cancer pain
2012 NIHR Horizon Scanning Centre (NIHR HSC) Ferumoxytol (Feraheme) for iron deficiency anaemia not associated with chronic kidney disease – first or second line
2012 NIHR Horizon Scanning Centre (NIHR HSC) CT-P13 (Infliximab biosimilar) for rheumatoid arthritis
2012 NIHR Horizon Scanning Centre (NIHR HSC) Rilonacept for gout
2012 NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoActemra) for active polyarticular juvenile idiopathic arthritis – second line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Pitolisant for hypersomnia and narcolepsy in patients with Parkinson's disease
2012 NIHR Horizon Scanning Centre (NIHR HSC) Davunetide intranasal for progressive supranuclear palsy – first line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Dexpramipexole for amyotrophic lateral sclerosis
2012 NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Placental growth factor based tests for the diagnosis of pre-eclampsia
2012 NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: DuoFertility ovulation prediction system to aid natural conception
2012 NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: VERV™ patient managed transdermal neuromodulation system for overactive bladder syndrome
2012 NIHR Horizon Scanning Centre (NIHR HSC) RePneu™ lung volume reduction coils for emphysema
2012 NIHR Horizon Scanning Centre (NIHR HSC) WOUNDCHEK™ Protease status point of care test for chronic wounds
2012 Institute for Clinical Evaluative Sciences (ICES) Health outcomes for better information and care (HOBIC): acute care in Ontario
2012 Institute for Clinical Evaluative Sciences (ICES) Ontario stroke evaluation report 2012: prescribing system solutions to improve stroke outcomes
2012 Institute for Clinical Evaluative Sciences (ICES) Hospital care for all: an equity report on differences in household income among patients at Toronto Central Local Health Integration Network (TC LHIN) hospitals, 2008-2010
2012 Institute for Clinical Evaluative Sciences (ICES) Seven more years: the impact of smoking, alcohol, diet, physical activity and stress on health and life expectancy in Ontario
2012 Institute for Clinical Evaluative Sciences (ICES) Regional measures of diabetes burden in Ontario
2012 Institute for Clinical Evaluative Sciences (ICES) Comparison of primary care models in Ontario by demographics, case mix and emergency department use, 2008/09 to 2009/10
2012 Institute for Clinical Evaluative Sciences (ICES) Payments to Ontario physicians from ministry of health and long-term care sources, 1992/93 to 2009/10
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin's lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL)
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of bone tumors (osteoid-osteoma and osseus metastases]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for the treatment of head and neck cancer]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for the treatment of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for the treatment of breast cancer]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of primary tumors of the gastrointestinal tract (colorectal and pancreatic cancer)]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Sling suspension in male urinary incontinence]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Stem cell therapy for urinary stress incontinence]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Intraoperative radiotherapy for primary breast cancer]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneous repair of mitral regurgitation with the MitraClip]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Renal denervation in patients with essential hypertension]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Impact evaluation and environmental analysis
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Outpatient cardiac rehabilitation. part V: study protocol, multi-centre prospective controlled observational study with two parallel groups on outpatient cardiac phase III rehabilitation]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy. Part I: status quo in Austria and part II: occupational therapy for rheumatoid arthritis]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy part III. Occupational therapy for patients after stroke]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Occupational therapy for dementia and depression]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Extracorporeal shock wave therapy (ESWT) for the treatment of delayed union or non-union of fractures]
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer
2012 Adelaide Health Technology Assessment (AHTA) Genetic testing for hereditary mutations in the VHL gene that cause von Hippel-Lindau syndrome
2012 Health Information and Quality Authority (HIQA) Health technology assessment of a national deep brain stimulation service in Ireland
2012 Institute of Health Economics (IHE) First and second trimester prenatal screening for trisomies 13, 18, and 21 and open neural tube defects
2012 Institute of Health Economics (IHE) Bariatric treatments for adult obesity
2012 Institute of Health Economics (IHE) Insulin pump therapy for type 1 diabetes
2012 NIHR Horizon Scanning Centre (NIHR HSC) Ponatinib for chronic myeloid leukaemia or Ph+ acute lymphoblastic leukaemia
2012 NIHR Horizon Scanning Centre (NIHR HSC) Liposomal cisplatin (Nanoplatin) for advanced non-small cell lung cancer – first line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Liposomal cisplatin (Lipoplatin) in combination with gemcitabine for pancreatic cancer – first line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Enzalutamide for chemotherapy naive castration-resistant prostate cancer
2012 NIHR Horizon Scanning Centre (NIHR HSC) Trametinib in combination with dabrafenib for V600 BRAF positive advanced malignant melanoma – first line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Carfilzomib (Kryprolis) for multiple myeloma – third line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Bortezomib (Velcade) in combination with dexamethasone or pegylated liposomal doxorubicin for relapsed multiple myeloma
2012 NIHR Horizon Scanning Centre (NIHR HSC) Bortezomib (Velcade) for newly diagnosed mantle cell lymphoma – first line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Hybrid PET/MR systems for whole-body diagnostic imaging
2012 NIHR Horizon Scanning Centre (NIHR HSC) SentiMag® and Sienna+® system for sentinel lymph node biopsy in breast cancer
2012 NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Infrared lasers for treating onychomycosis
2012 NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: ThromboLUX™ for determining platelet quality
2012 NIHR Horizon Scanning Centre (NIHR HSC) Sofosbuvir for chronic hepatitis C infection with compensated liver disease
2012 NIHR Horizon Scanning Centre (NIHR HSC) Simeprevir for chronic hepatitis C infection
2012 NIHR Horizon Scanning Centre (NIHR HSC) Simeprevir for hepatitis C – first line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Nalmefene (Selincro) for the reduction of alcohol consumption – first line pharmacological therapy for alcohol dependence
2012 NIHR Horizon Scanning Centre (NIHR HSC) GSK-2402968 (Drisapersen) for duchenne muscular dystrophy – first line
2012 NIHR Horizon Scanning Centre (NIHR HSC) Ustekinumab (Stelara) for psoriatic arthritis
2012 NIHR Horizon Scanning Centre (NIHR HSC) Secukinumab for moderate to severe, active rheumatoid arthritis
2012 NIHR Horizon Scanning Centre (NIHR HSC) EPI-743 for mitochondrial disease – first line
2012 NIHR Horizon Scanning Centre (NIHR HSC) BIIB-017 for relapsing forms of multiple sclerosis
2012 Adelaide Health Technology Assessment (AHTA) Genetic testing for the diagnosis or prediction of Long QT Syndrome
2012 Andalusian Health Technology Assessment Area (AETSA) [Protease inhibitors (Boceprevir and telaprevir) in the treatment of chronic HCV infection: relative efficacy, safety and efficiency]
2012 NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Amniotic fluid lactate™ monitoring system for dysfunctional labour
2012 NIHR Horizon Scanning Centre (NIHR HSC) Masitinib for severe asthma
2012 NIHR Horizon Scanning Centre (NIHR HSC) Omalizumab for chronic spontaneous urticaria – second line
2012 Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of genetic tests for screening of colorectal cancer]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Anti-angiogenic drugs in the treatment for age-related macular degeneration: issues associated with their use in Québec]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Sentinel lymph node biopsy in breast cancer treatment: indications and contraindications]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Overview of the use of antihypertensive agents by adults covered by the Québec public prescription drug insurance plan]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Complications associated with the surgical instruments used in tonsillectomies]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Diagnosis and treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in people with Multiple Sclerosis (MS)]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Organization and provision of rehabilitation services for stroke patients and their families: a review of the evidence]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [NOTICE – Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Sentinel lymph node biopsy in breast cancer treatment: efficacy and safety]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Study of antipsychotic use. Part 3 : Adults aged 25 or older, primarily those 65 or older diagnosed with dementia]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Quality indicators for primary care professionals and managers]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Immunochemical fecal occult blood. Determination of a positivity threshold for the upcoming demonstration projects under Québec's colorectal cancer screening program]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Promising measures to reduce the use of avoidable obstetrical interventions with low-risk women]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Evaluation of the evidence on the HeartMate II and HeartWare ventricular assist devices for the treatment of chronic end-stage heart failure]
2012 Institut national d'excellence en sante et en services sociaux (INESSS) [Specialized services for people with alzheimer's disease]
2012 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Paliperidone palmitate (Xeplion®) 50 mg, 75 mg, 100 mg and 150 mg prolonged release suspension for injection
2012 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Bupivacaine hydrochloride (1 mg/ml or 1.25 mg/ml) and fentanyl (2 micrograms/ml) solution for infusion (Bufyl®)
2012 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Colecalciferol (Fultium-D3®) 800 IU capsules